Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

Pharmaceutical shares are drawing renewed attention as investors rotate away from technology names. AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs, a move that coincides with a broader pullback in tech stocks. The pattern is a familiar one: when growth-heavy sectors wobble, capital often migrates toward businesses seen as steadier, and large-cap drugmakers fit that description for many portfolios.

What makes the sector's appeal more than purely defensive is its earnings profile. Large pharmaceutical companies typically generate cash flows that are less tied to the economic cycle, supported by patent-protected products and ongoing demand for treatments. That combination of relative stability and growth potential can make the group attractive when investors are reassessing risk elsewhere.

For observers, the key question is whether this rotation persists or proves temporary. Watch upcoming earnings reports, drug pipeline updates and regulatory decisions, since these company-specific catalysts ultimately determine whether the sector's premium valuations hold. Also worth monitoring is whether tech weakness deepens or stabilizes, as that will influence how long the defensive bid lasts.